Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.72 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.72 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.72 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.72 |
| ▸ | ABCG2 | Q9UNQ0 | 15/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14344386 | 0.91 | PRKD3 (0.58) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL12261412 | 0.88 | PRKD3 (0.56) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL14344388 | 0.88 | PRKD3 (0.55) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL1064782 | 0.86 | ABCG2 (0.59) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL29831976 | 0.86 | ABCG2 (0.59) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL5555419 | 0.86 | TGFBR1 (0.53) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL14344377 | 0.85 | ABCG2 (0.59) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL2394048 | 0.84 | ABCG2 (0.52) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL29381400 | 0.84 | TGFBR1 (1.00) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL29361383 | 0.84 | TGFBR1 (1.00) | TGFBR1PRKD3PRKD1PRKD2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604685-B1 | METHOD OF PRODUCING PANCREATIC HORMONE-PRODUCING CELLS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-9157069-B2 | Method of producing pancreatic hormone-producing cells | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | disclosed |
| US-20130210060-A1 | METHOD OF PRODUCING PANCREATIC HORMONE-PRODUCING CELLS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-15 | — | — | US | disclosed |
| EP-2604685-A1 | METHOD OF PRODUCING PANCREATIC HORMONE-PRODUCING CELLS | Takeda Pharmaceutical Company Limited (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-8022077-B2 | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-09-20 | — | — | US | disclosed |
| US-8022077-B2 | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-09-20 | — | — | US | disclosed |
| EP-1888580-B1 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARM LTD (IE) | 2010-03-03 | — | — | EP | disclosed |
| US-20090131460-A1 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-05-21 | — | — | US | disclosed |
| EP-1888580-A2 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | Tibotec Pharmaceuticals Ltd. (IE) | 2008-02-20 | — | — | EP | disclosed |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| WO-2006120252-A2 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131460-A1 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF | DPYD, TYMP, PNP | TGFBR1 3996/4885PRKD3 1016/4885PRKD1 1577/4885 |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SMAD3, SMAD2, TGFB2 | TGFBR1 8/4885PRKD3 1661/4885PRKD1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.